

EXHIBIT A

Curriculum Vitae

Gary A. Levy, MD, FRCP(C)

(Last Updated: April 22, 2003)

I. Education

1966		Forest Hill Collegiate, Toronto, Canada
1969	B.Sc.	University of Toronto, Toronto, Canada
1973	M.D.	University of Toronto, Toronto, Canada
1978	F.R.C.P.(C)	Internal Medicine
1978	F.R.C.P.(Gastro)	Gastroenterology

II. Postgraduate Education

1973-74	Intern, Rotating	Mount Sinai Hospital, Toronto, Canada
1974-75	Resident, Internal Medicine	Toronto General Hospital, Toronto, Canada
1975-76	Resident, Internal Medicine	Mount Sinai Hospital, Toronto, Canada
1976-77	Resident, Gastroenterology	St. Michael's Hospital, Toronto, Canada
1977-78	Resident, Gastroenterology	Sunnybrook Health Science Centre, Toronto, Canada
1979-81	Fellow, Immunology	Scripps Clinic and Research Foundation, La Jolla, CA

Gary A. Levy, MD

III. Academic Appointments

1981-85	Consultant, Gastroenterology	Sunnybrook Medical Centre, Toronto, Canada
1981-85	Assistant Professor of Medicine	Department of Medicine, University of Toronto, Toronto, Canada
1985-present	Consultant, Gastroenterology	Mt. Sinai Hospital, Toronto, Canada
1985-present	Associate Staff	Toronto General Hospital Toronto, Canada
1986-1990	Associate Professor of Medicine	Department of Medicine, University of Toronto, Toronto, Canada
1986-89	Co-Director Liver Transplant Program	University of Toronto Toronto, Canada
1989-92	Director GI Transplant Program	University of Toronto Toronto, Canada
1989-present	Director Research, Transplant Program	University of Toronto Toronto, Canada
1990-present	Division Director Div. of Gastroenterology	University of Toronto Toronto, Canada
1990-present	Professor of Medicine	Department of Medicine University of Toronto Toronto, Canada
1992-present	Program Director	Multi-Organ Transplant Program University Health Network University of Toronto
1995-96	Vice-President	Canadian Association of Gastroenterology

Gary A. Levy, MD

1996-97	President-Elect	Canadian Association of Gastroenterology
1997-98	President	Canadian Association of Gastroenterology
1998-2000	Past-President	Canadian Association of Gastroenterology
2000-	President	Canadian Digestive Health Foundation

IV. Graduate Faculty

Department of Pathology	1984-present
Institute of Medical Science	1986-present
Department of Immunology	1986-present

V. Teaching

University of Toronto Undergraduate Immunology Course	1996
University of Toronto Undergraduate Immunology Course	1997
University of Toronto Undergraduate Immunology Course	1998
University of Toronto Undergraduate Immunology Course	1999
University of Toronto Undergraduate Immunology Course	2000
University of Toronto Undergraduate Immunology Course	2001
University of Toronto Undergraduate Immunology 1020S	
Recent Advances in Clinical Immunology	March 2001
University of Toronto Graduate LMP 1020S	
Inflammation, Immunity and Immunopathology	March 2001

Gary A. Levy, MD

University of Toronto Undergraduate Immunology Course	2002
University of Toronto Undergraduate Immunology Course	2003
University of Toronto Undergraduate Immunology 1020S Recent Advances in Clinical Immunology Title: Immunology of Transplant Rejection	March 13, 2003
University of Toronto Graduate LMP 1020S Inflammation, Immunity and Immunopathology Title: Current Advances in Allogeneic and Xenogeneic Transplantation	April 3, 2003

VI. Awards and Honours

1966	Ontario Secondary School Scholarship
1971	Hospital For Sick Children Summer Scholarship
1972	Canadian Liver Foundation Summer Scholarship
1979-81	Medical Research Council of Canada Fellowship
1981	Medical Research Council of Canada Scholarship
1983	William Goldie Prize in Medicine
1988	Elected to the American Society for Clinical Investigation
1988	William Goldie Prize in Medicine
1994	Canadian Association of Gastroenterology Visiting Research Professor
1994	Vice President, Canadian Association of Gastroenterology
1995	Sandoz Award, Clinical Research Society of Toronto
1996	Department of Medicine Research Award, University of Toronto

Gary A. Levy, MD

- | | |
|------|---|
| 2001 | Honorary Professor, Wuhan University, People's Republic of China |
| 2002 | Canadian Liver Foundation Commemorative Medal for the Queen's Jubilee |

VII.

Chief Scientific Officer - Transplantation Technologies Inc. 1997-2002

VIII. Research Experience

- | | |
|---------|---|
| 1967-68 | Hospital for Sick Children, Toronto
Lipid Research |
| 1968-69 | Hospital for Sick Children, Toronto
Vitamin E Research |
| 1970-71 | Department of Medicine, University of Toronto
Radioimmunoassay of Bile Acids |
| 1971-72 | Department of Medicine, University of Toronto
Bile Acid Metabolism |
| 1978 | Surmontil and Duodenal Ulcer Disease |
| 1979-81 | Scripps Clinic and Research Foundation, La Jolla, CA
Immunology of the Liver-Viral Induced Liver Injury. |

VIX. Publications

A. Original Research Manuscripts

1. Levy, G.A. and Edgington, T.S. Lymphocyte co-operation is required for amplification of macrophage procoagulant activity. J. Exp. Med. 151:1232:1980.
2. Levy, G.A. and Edgington, T.S. Lymphocyte procoagulant activity and mitogenesis in the C3H/HeJ mouse: Discordant response to lipopolysaccharide stimulation. J. Immunology 124:2665:1980.
3. Schwartz, B.S., Levy, G.A., Curtiss, L.K., Fair, D.S., and Edgington, T.S. Plasma lipoprotein induction and suppression of procoagulant activity in-vitro. I. Two procoagulant activities are produced by peripheral blood mononuclear cells. J. Clin. Invest. 67:1650:1981.
4. Levy, G.A., Schwartz, B.S., Curtiss, L.K. and Edgington, T.S. Plasma lipoprotein

Gary A. Levy, MD

induction and suppression of procoagulant activity in-vitro. II. The requirement for cellular collaboration. J. Clin. Invest. 77:1614:1981.

5. Levy, G.A., Schwartz, B.S. and Edgington, T.S. The kinetics and metabolic requirements for direct lymphocyte induction of human procoagulant monokines by bacterial lipopolysaccharide. J. Immunology. 127:357:1981.
6. Levy, G.A., Saibil, F.S. and Saibil, E. An unusual case of hepatic calcification. Medicine. 185:1284:1981.
7. Levy, G.A., Leibowitz, J.L., and Edgington, T.S. Induction of monocyte procoagulant activity by murine hepatitis virus type 3 parallels disease susceptibility in mice. J. Exp. Med. 154:1385:1981.
8. Levy, G.A., and Edgington, T.S. The major histocompatibility complex requirement for cellular collaboration in the murine lymphoid procoagulant response by bacterial lipopoly-saccharide. J. Immunology. 128:1284:1982.
9. Schwartz, B.S., Levy, G.A. and Edgington, T.S. Immune- complex induced human monocyte procoagulant activity. II Cellular kinetics and metabolic requirements. J. Immunology 128:1037:1982.
10. Schwartz, B.S., Levy, G.A., Fair, D.S. and Edgington, T.S. An inducible prothrombinase of murine monocytes. J. Exp. Med. 155:1464:1982.
11. Leibowitz, J.L., Fung, L.S. and Levy, G.A. A sensitive radioimmunoassay for the detection of antibodies to MHV-3. J. Virol. Methods. 3:255:1983.
12. Levy, G.A., MacPhee, P., Fung, L.S., Fisher, M.M. and Rappaport, A.M. The effects of MHV-3 infection on the microcirculation of the liver. Hepatology 3:964:1983.
13. Ottaway, C.A., Warren, R.E., Saibil, F.S., Fung, L.S. and Levy, G.A. Monocyte procoagulant activity in Whipple's disease. J. Clin. Immunol. Sep;4(5):348-58:1984.
14. Levy, G.A., Shaw, R., Leibowitz, J.L. and Cole, E. The immune response to mouse hepatitis virus: Genetic variation in antibody response and disease. Adv. In Exp. Biol. and Medicine. 173:345:1984.
15. Levy, G.A., MacPhee, P.J., Fung, L.S., Fisher, M.M. and Rappaport, A.M. The effects of mouse hepatitis virus type 3 on the microcirculation of the liver in inbred strains of mice. Adv. In Exp. Med. and Biol. 173:397:1984.
16. Levy, G.A., Helin, H. and Edgington, T.S. The pathobiology of viral hepatitis and

immunologic activation of the coagulation protease network. *Seminars in Liver Disease*. 4:59:1984.

17. Levy, G.A., Schwartz, B.S., Curtiss, L.K. and Edgington, T.S. The regulatory role of Tu and Tg cells in the cellular initiation of the extrinsic coagulation pathway by bacterial lipopolysaccharide. *J. Clin. Invest.* 76:548:1985.
18. MacPhee, P.J., Dindzans, V.J., Fung, L.S. and Levy, G.A. Acute and chronic changes in the microcirculation of the liver in inbred strains of mice following infection with mouse hepatitis virus type 3. *Hepatology*. 5:649:1985.
19. Cole, E.H., Shulman, J., Urowitz, M., Keystone, E., Williams, C. and Levy, G.A. Monocyte procoagulant activity in glomerulonephritis associated with systemic lupus erythematosus. *J. Clin. Invest.* 75:861-868:1985.
20. Cole, E.H., Cardella, C., Williams, C., Schulman, J. and Levy, G.A. Monocyte procoagulant activity (MPCA) and plasminogen activator (MPA): Role in human renal allograft rejection. *Transplantation*. 40:363:1985.
21. Dindzans, V.J., MacPhee, P.J., Fung, L.S., Leibowitz, J.L. and Levy, G.A. The immune response to mouse hepatitis virus: Expression of monocyte procoagulant activity and plasminogen activator during infection in-vivo. *J. Immunology*. 135(6):4189-4197:1985.
22. Shaw, R., Cole, E.H., Leibowitz, J.L. and Levy, G.A. The immune response to mouse hepatitis virus: Genetic variation in antibody response and disease. *J. Gen. Virol.* 138:2128:1985.
23. Dindzans, V.J., Skamene, E. and Levy, G.A. Susceptibility/resistance to murine hepatitis virus strain 3 (MHV-3) and monocyte procoagulant activity (MPCA) are genetically linked and controlled by 2 Non H-2 linked genes. In: *Genetic control of host resistance: Progress in Leukocyte Biology*. 3:151:1985.
24. Dindzans, V.J., Skamene, E. and Levy, G.A. Susceptibility/resistance to murine hepatitis virus strain 3 (MHV-3) and monocyte procoagulant activity (MPCA) are genetically linked and controlled by 2 Non H-2 linked genes. *J. Immunol.* 136:2355:1986.
25. Cole, E.H., Sweet, J. and Levy, G.A. Induction of monocyte procoagulant activity in the BXSb mouse: An important mediator in glomerulonephritis. *J. Clin. Invest.* 78:1:1986.
26. Cohen, Z., Silverman, R.E., Wassef, R., Levy, G.A., Burnstein, M., Cullen, J., Makowka, L., Langer, B. and Greenberg, G.R. Small intestinal transplantation using cyclosporine A (CsA): Report of a Case. *Transplantation*.

42:613-620:1986.

27. Abecassis, M., Falk, R.E., Falk, J.A., Makowka, L. and Levy, G.A. 16,16 Dimethyl Prostaglandin E₂ (PGE₂) prevents the development of fulminant hepatitis and blocks the induction of monocyte procoagulant activity (PCA) following murine hepatitis virus strain 3 (MHV-3) infection. *J. Clin. Invest.* 80:881:1987.
28. Dindzans, V.J., Zimmerman, B., Sherker, A. and Levy, G.A. Susceptibility to mouse hepatitis virus strain 3 in BALB/cJ mice: Failure of immune cell proliferation and interleukin 2 production. *Adv. in Exp. Med and Biol.* 218:411-420:1987.
29. Abecassis, M., J. Falk, L. Makowka, V. Dindzans, R. Falk and G. Levy. Cyclosporin A (CsA) fails to alter innate resistance to murine hepatitis virus strain 3 (MHV-3) infection in A/J mice. *Advances in Med. and Biol.* 218:437- 440:1987
30. Abecassis, M., V. Dindzans, W. Lopatin, L. Makowka, J. Falk, G. Levy and R. Falk. Prostaglandin E₂ (PGE₂) prevents fulminant hepatitis and the induction of procoagulant activity (PCA) in susceptible animals. *Advances in Exp. Med. and Biol.* 218:437-440:1987.
31. Silverman, R., Cohen, Z., Levy, G., Craig, M., Cullen, J. and Langer, B. Immune responses in small intestinal transplantation in the rat: correlation of histopathology and monocyte procoagulant activity (PCA). *Surgery.* 102:395:1987.
32. Abecassis, M., Wong, P.Y., Cheung, F., Greig, P., Taylor, B., Langer, B., Strasberg, S. and Levy, G. Cyclosporin A metabolites (CM) suppress proliferation by concanavalin A (Con A) and in a mixed lymphocyte reaction (MLR). *The Canadian Journal of Surgery.* 31:145-150:1987.
33. Rosenthal, G.A., Levy, G.A., Rotstein, O.D. *Bacteroides Fragilis* induces procoagulant activity by macrophages: A potential mechanism for abscess formation. *Surgical Forum.* 24:103-104:1988.
34. Levy, G., Abecassis, M. Activation of the immune coagulation system by the coronavirus murine hepatitis virus strain 3. *Annual Reviews of Infectious Diseases.* 11(4):S712-S721:1989.
35. Wakefield, A.J., Cohen, Z., Craig, M., Connolley, P., Jeejeebhoy, K.N. Silverman, R. and Levy, G.A. The thrombogenicity of TPN solutions: I. Effect on induction of monocyte/macrophage procoagulant activity. *Gastroenterology* 97(5):1210-1219:1989.
36. Wakefield, A.J., Cohen, Z., Rosenthal, M. Craig, M., Jeejeebhoy, K.N., Gottlieb, A. and Levy, G.A. The Thrombogenicity of Total Parenteral Nutrition Solutions:

Gary A. Levy, MD

II. Effect of Induction of Endothelial Cell Procoagulant Activity. *Gastroenterology* 97(5):1220-1228:1989.

37. Silverman, R.E., Cohen, Z., Craig, M., Langer, B. and Levy, G.A. Monocyte/macrophage procoagulant activity (PCA) as a measure of immune responsiveness in Lewis and Brown Norway inbred rats: Discordance with lymphocyte proliferative assays. *Transplantation*. 47:542-548:1989.
38. Greig, P., Woolf, G., Sinclair, S.B., Abecassis, M., Strasberg S.M., Taylor, Blendis, L., B., Superina, R., Glynn, M.F.X., Langer, B. and Levy, G.A. Treatment of Primary Liver Graft Non-Function with Prostaglandin E₁. *Transplantation*. 48(3):447-453:1989.
39. Rosenthal, G.A., Levy, G.A., Rotstein, O.D. Induction of macrophage procoagulant activity by bacteroides fragilis. *Infection and Immunity*. 57:338-343:1989.
40. Goldberg, H.J., Wong, P.Y., Cole, E.H., Levy, G.A and Skorecki, K.L. Dissociation between the immunosuppressive activity for cyclosporine derivatives and their effects on intracellular calcium signalling in mesangial cells. *Transplantation*. 47(4):731-733:1989.
41. Sinclair, S.B., Greig, P.D., Blendis, L.M., Abecassis, M., Roberts, E.A., Phillips, M.J., Cameron, R., Levy, G.A. Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E: A preliminary report. *Journal of Clinical Investigation*. 84:1063-1069:1989.
42. Sinclair, S.B., Wakefield, A. and Levy, G.A. Fulminant Hepatitis. In: *Immunopathology of Liver Disease*. Springer Seminars in Immunopathology, H. C. Thomas eds. Springer- Verlag 12:1-13:1990
43. Kim, P.C.W., Cohen, Z., Craig, M., Cullen, J. and Levy G.A. Characterization of Immune Responses in Different Lymphoid Compartments During Small Intestinal Allograft Rejection: Correlation Between Procoagulant Activity (PCA) and Histopathology. *Am. J. Surgery*. 159:161-166:1990.
44. Wanless, I.R., Dore, S., Gopinath, N., Tan, J., Cameron, R., Heathcote, E.J., Blendis, L.M., Levy, G. Histopathology of cocaine hepatotoxicity: Report of four cases. *Gastroenterology*. 98:497-501:1990.
45. Wu, T.W., Samuel, C.K. Yiu, Au, J.X., Greig, P.D., Strasberg, S.M., Ettles, M., Abecassis, M., Superina, R.A., Langer, B., Blendis, L.M., Phillips, M.J., Taylor, B.R., Levy, G.A. Conjugated and delta bilirubin are complementary markers of rejection in liver transplant recipients. *Clinical Chemistry*. 36(3):9-14:1990.
46. Cole, E.H., Sweet, J., Laskin, C. and Levy, G.A. The effect of defibrinating agent

- (ancrod) on intrarenal fibrin deposition, macrophage PCA and survival in the BXSB model of systemic lupus erythematosus. *Kidney Int'l.* 37:29-35:1990.
47. Wakefield, A., Cohen, Z. and Levy, G. Procoagulant Activity in Gastroenterology. *Gut.* 31:239-41:1990.
 48. Flowers, M., Wanless, I., Heathcote, J., Inman, R., Sherman, M., Reynolds, W., Cameron, R., Levy, G.A. Fulminant Hepatitis as a Consequence of Reactivation of Hepatitis B Virus Infection Following Withdrawal of Low Dose Methotrexate Therapy. *Annals of Internal Medicine.* 112:381-2:1990.
 49. Sinclair, S.B., Rotstein, O.D., Levy, G.A. Disparate induction of procoagulant activity by live and inactivated bacteria and viruses. *Infection and Immunity.* 58(6):1821-27:1990.
 50. Sinclair, S., Abecassis, M., Wong, P.Y., Romaschin, A., Fung, L.S. and Levy, G.A. Mechanism of protective effect of prostaglandin E in murine hepatitis virus strain 3 infection: Effects on macrophage production of tumour necrosis factor, procoagulant activity and leukotriene B₄. *Adv. Exp. Med. and Biol.* 1990:276:533.
 51. Kim, P., Cohen, Z., Craig, M., Cheung, F., Wong, P.Y., Cullen, J. and Levy, G.A. Effects of cyclosporin A (CsA) and cyclosporin A metabolites (CM) in experimental small intestinal transplantation (SIT). *Transplantation* 40(6):1990.
 52. Chung, S.W., Sinclair, S.B., Leibowitz, J.L., Skamene, E., Levy, G.A. Cellular and metabolic requirements for induction of macrophage procoagulant activity by murine hepatitis virus strain 3 in-vitro. *J. Immunol.* 146:271- 278:1991.
 53. Fung, L.S., Neil, G., Leibowitz, J., Cole, E.H., Levy, G.A. Monoclonal antibody analysis of a unique procoagulant activity induced by murine hepatitis virus strain 3 infection. *J. Biol. Chem.* 1991:266:1789-1795.
 54. Chung, S., Greig, P.D., Levy, G.A. Postoperative management of the liver transplant patient. *Medicine North America.* 1991:16:2100-2107.
 55. Phillips, M.J., Blendis, L.M., Poucell, S., Patterson, J., Petric, M., Roberts, E., Levy, G.A., Superina, R.A., Greig, P.D., Langer, B., Purcell, R.H. Syncytial giant cell hepatitis: sporadic hepatitis with distinctive pathology, severe clinical course and paramyxoviral features. *New England Journal of Medicine.* 1991:324:455-460.
 56. Chung, S., Langer, B., Levy, G. Identification and regulation of macrophage procoagulant activity (PCA) in a murine model of viral hepatitis (MHV-3). *Surgical Forum.* XLI:88-91:1991.

57. Levy, G.A. and Sinclair S. Treatment of Fulminant Hepatic Failure with Prostaglandins. *Digestive Diseases and Sciences*. 1991;36(6):791.
58. Chung, S., Kim, P., Koh, I., Cohen, Z., Levy, G. Allogeneic stimulation of monocyte/macrophage procoagulant activity - cellular kinetics and inhibition by cyclosporin A and dmPGE₂. *Immunology* 1991;42(6):501-513.
59. Clavien, P., Morgan, G., Sanabria, J., Petrunka, C., Levy, G., Harvey, R., Strasberg, S. Effect of cold preservation on lymphocyte adherence in the perfused rat liver. *Transplantation*. 1991;52(3):412-417.
60. Chung, S., Sinclair, S., Fung, L.S., Levy, G. Effect of eicosanoids on induction of procoagulant activity by murine hepatitis virus strain 3 in vitro. *Prostaglandins*. 1991;42(6):501-513.
61. Li, C., Fung, L.S., Crow, A., Myers-Mason, N., Leibowitz, J., Cole, E., Levy, G. Monoclonal anti-prothrombinase (3D4.3) prevents mortality from murine hepatitis virus infection (MHV-3). *J. Exp. Med.* 1992;176:689-697.
62. Phillips, M.J., Cameron, R., Flowers, M.A., Blendis, L.M., Greig, P.D., Wanless, I., Sherman, M., Superina, R., Langer, B. Post-transplant recurrent HBV liver disease: Viral burden, steato-viral and fibro-viral hepatitis B. *American Journal of Pathology*. 1992;140(6):1295-1308.
63. Koh, I., Kim, P., Chung, S., Oziel, P., Fung, L., Mason, N., Wong, P.Y., Cullen, J., Levy, G., Cohen, Z. The effects of 16,16 dimethyl prostaglandin E2 therapy alone and in combination with low-dose cyclosporine on a rat small intestinal transplantation. *Transplantation*. 1992;54(4):592-598.
64. Holloway, C., Chung, S., Strasberg, S., Levy, G. Mechanisms of liver preservation injury. *Journal of Applied Physiology*. 1992;6(suppl):28-31.
65. Cywes, R., Greig, P.D., Sanabria, J.R., Clavien, P., Levy, G.A., Harvey, P.R.C., Strasberg, S.M. Effect of intraportal glucose infusion on hepatic glycogen content and degradation, and outcome of liver transplantation. *Ann. Surg.* 1992; 216(3):235-236.
66. Fingerote, R., Levy, G.A. Mechanisms and Treatment of Ischemic Reperfusion Liver Injury. *Transplantation*. 1992;3(4):154-161.
67. Clavien, P-A., Harvey, P.R.C., Sanabria, J., Cywes, R., Levy, G., Strasberg, S.M. Mechanisms and effects of lymphocyte adherence in the reperfused rat liver. *Hepatology*. 1993;17(1):131-142.

68. Liu, G., Butany, J., Wanless, I., Cameron, R., Greig, P., Levy, G. The vascular pathology of human hepatic allografts. *Human Pathology*, 1993;24(2):182-188.
69. Cywes, R., Mullen, J.B.M., Stratis, M.A., Greig, P.D., Levy, G.A., Harvey, P.R.C., Strasberg, S.M. Prediction of the outcome of transplantation in man by platelet adherence in donor liver allografts. *Transplantation*. 1993;56:316-323.
70. Donaldson, B.W., Gopinath, R., Wanless, I.R., Phillips, M.J., Cameron, R., Roberts, E.A., Greig, P.D., Levy, G.A., Blendis, L.M. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. *Hepatology*, 1993;18(6):1370-1376.
71. Cameron, R.G., Greig, P.D., Farber, E., Wilson, S., Sherman, M., Levy, G.A., Phillips, M.J. Small encapsulated hepatocellular carcinoma of the liver. *Cancer*, 1993;72(9):2550-2559.
72. Koh, I., Cohen, Z., Levy, G., Plapler, H., Wojcik, D., Gorczynski, R. Migration patterns of lymphocytes following syngeneic heterotopic small bowel transplantation in rodents. *Immunology Letters* 1993;38:3-9.
73. Gorczynski, R.M., Cohen, Z., Plapler, H., Levy, G.A., Wojcik, D., Koh, I. Functional activity in host and graft lymphoid tissue of rats receiving syngeneic heterotopic small bowel transplants with portal or systemic drainage. *Immunology Letters* 1993;38:189-194.
74. Chung, S., Downey, G., Rotstein, O., Levy, G. Early cellular events in the induction of murine hepatitis virus (MHV-3) induced macrophage procoagulant activity (PCA). *Adv. in Exp. Med. and Biol.* 1993;342:385-388.
75. Chung, S., Li, C., Fung, L.S., Crow, A., Gorczynski, R., Cole, E., Perlman, S., Leibowitz, J., Levy, G. Role of macrophage procoagulant activity in mouse hepatitis virus (MHV) infection: Studies using T cell MHV-3 clones and monoclonal antibody 3D4.3. *Adv. Exp. Med. Biol.* 1993;342:377-384.
76. Chung, S.W., Toth, J.L., Rezieg, M., Cameron, R., Taylor, B.R., Greig, P.D., Levy, G.A., Langer, B. Liver transplantation for hepatocellular carcinoma. *American Journal of Surgery*. 167:317-321:1994 (March).
77. Cattral, M.S. and Levy, G.A. Artificial liver support - Pipe dream or reality. *New England Journal of Medicine*. 331:268-269:1994 (July).
78. Flowers, M., Sherker A.S., Sinclair, S., Sherman, M., Blendis, L., Cameron, R., Phillips, M.J., Greig, P. and Levy, G. Prostaglandin E in the Treatment of Recurrent Hepatitis B Infection Following Orthotopic Liver Transplantation. *Transplantation*, 58:183-191, July 1994.

Gary A. Levy, MD

79. Chung, S., Nisbet-Brown, E., Gorczynski R., Skamene, E., Perlman, S., Leibowitz, J., Fung, L.S., Crow, A., Myers-Mason, N., Flowers, M., Levy, G. A TH1 helper cell line (3E9.1) from resistant A/J mice inhibits induction macrophage procoagulant activity (PCA) in vitro and protects against MHV-3 mortality in vivo. *Immunology*. 1994;83:353-361.
80. Cattral, M., Altraif, I., Greig, P.D., Blendis, L., Levy, G.A. Toxic effects of intravenous and oral prostaglandin E therapy in patients with liver disease. *American Journal of Medicine*, 1994;97:369-373.
81. Clavien, P.A., Camargo C.A., Croxford, R., Langer, B., Levy, G.A., Greig, P.D. Definition and classification of negative outcomes in organ transplantation. Application in Liver Transplantation. *Annals of Surgery*, 1994;220(2):109-20.
82. Laskin C., Chuma, A., L. Angelov, G. Neil, Levy, G.A., Mason, N., Soloninka, C., Cole, E. Sera from habitual aborters induce monocyte procoagulant activity: A lymphocyte dependent event. *Clinical Immunology and Immunopathology*. 1994;73(2):235-244.
83. Gorczynski, R.M., Chan, Z., Chung, S., Cohen, Z., Levy, G., Sullivan, B., Fu, X.-M. Prolongation of rat small bowel or renal allograft survival by pre-transplant transfusion and/or by varying the route of allograft venous drainage. *Transplantation*, 1994;58[October](7):816-820.
84. Gorczynski, R.M., Cohen, Z., Fu, X.M., Levy, G.A., Plapler, H., Sullivan, B. Hepatic regulation of lymphocyte adhesion to, and activation on, syngeneic endothelial monolayers. *Immunology*, 1994;83:58-64.
85. Olivieri, N.F., Liu, P.P., Sher, G.D., Collins, A.F., McCusker, P.J., Levy, G., Greig, P., Daly, P., Francombe, W.H., Butany, J. Successful combined cardiac and liver transplantation in an adult with homozygous beta-thalassemia. *N Eng J Med*. 1994;330:1125-1127.
86. Fingerote, R.J., Cruz, B.M., Gorczynski, R., Fung, L.S., Hubbell, H.R., Suhadolnik, R.J., Levy, G.A. A 2',5'-oligoadenylate analogue inhibits murine hepatitis virus strain 3 (MHV-3) replication in vitro but does not reduce MHV-3 related mortality or induction of procoagulant activity in susceptible mice. *Journal of General Virology*, 1995:[April]76:373-380.
87. Cole, E.H., Neil, G., Isenman, D., Levy, G.A. Identification of the procoagulant inducing factor derived from the plasma of BXSB mice. *Autoimmunity* 1995;8:47-59, April.
88. Talbot, P. and Levy, G.A. The molecular biology, immunology and pathogenesis

- of corona- and related virus infections. Sixth International Symposium on Corona- and Related Viruses. *Trends in Microbiology*, 1995;3(4):127-129, April.
89. Wanless, I.R., Wong, F., Blendis, L.M., Greig, P., Heathcote, E.J., Levy, G. Role of hepatic and portal vein thrombosis in cirrhosis: Possible role for development of parenchymal extinction and portal hypertension. *Hepatology*, 1995;21(5):1238-1247.
 90. Terminology for Hepatic Allograft Rejection. World Gastroenterology Consensus Document. *International Working Party Hepatology*, 1995;22(2):648-654.
 91. Fingerote, R., Leibowitz, J., Levy, G.A. Treatment of resistant A/J mice with methyl prednisolone (MP) in loss of resistance to murine hepatitis virus strain 3 (MHV-3) and induction of macrophage procoagulant activity (PCA). In: Corona- and related viruses. Talbot PJ and Levy GA eds. Plenum Press, New York, pp. 89-94, 1995.
 92. Parr, R., Leibowitz, J., Fung, L.S., Reneker, S.J., Myers-Mason, N., Levy, G.A. MHV-3 induced PCA is a mouse fibrinogen-like protein (MusFiblp). In: Corona- and related viruses. Talbot PJ and Levy GA eds. Plenum Press, New York, pp. 151-158, 1995.
 93. Chung, S.W., Rotstein, O.D., Downey, G.P., Levy, G.A. Effect of alterations in early signal transduction events on the induction of procoagulant activity by murine hepatitis virus strain 3 in vitro. *Journal of General Virology*, 1995;76:1181-1187.[April].
 94. Freeman, D., Grant, D., Levy, G., Rochon, J., Wong, P.Y. Pharmacokinetic profile of Neoral, a new oral formulation of cyclosporine, in liver transplant recipients. *Therapeutic Drug Monitoring*, 1995;17:213-216. [January]
 95. Gorczynski, R.M., Chung, S., Fu, X.M., Levy, G., Sullivan, B, Chen, Z. Manipulation of skin graft rejection in alloimmune mice by anti-VCAM-1: VLA4 but not anti-ICAM-1 LFA-1 monoclonal antibodies. *Trans. Immunol.* 1995;3(1):55-61. [March]
 96. Pope, M., Rotstein, O., Cole, E., Sinclair, S., Parr, R., Cruz, B., Fingerote, R., Chung, S., Gorczynski, R., Fung, L., Leibowitz, J., Rao, Y.S., Levy, G.A. Pattern of disease after murine hepatitis virus strain 3 (MHV-3) infection correlates with macrophage activation and not viral replication. *Journal of Virology*, 1995;69(9):5252-5260, September.
 97. Parr, R., Leibowitz, J.L., Fung, L.S., Reneker, S.J., Myers-Mason, N., Levy, G.A. Association of a mouse fibrinogen-like protein with MHV induced prothrombinase activity. *Journal of Virology*, 1995;69(8):5033-5038. [May]

98. Qureshie, S., Clermont, S., Leibowitz, J., Fung, L.S., Levy, G., Malo, D. Murine hepatitis-3 induced prothrombinase (Fgl2) maps to proximal chromosome 5. *Genomics*, 1995;29:307-309. [July]
99. Chung, S.W., Gorczynski, R.M., Dziadkowiecz, I., Levy, G.A. Induction of T cell hyporesponsiveness by intrahepatic modulation of donor antigen-presenting cells. *Immunology* 1995;85:582-590.[April]
100. Liu, W.T., Levy, G.A., Wong, P.Y. The measurement of AM19 and other metabolites in the blood of liver transplant patients with stable liver function. *Therapeutic Drug Monitoring*, 1995;17:479-486, March.
101. Dackiw, A.P.B., Zackrzewski, K., Fingerote, R., Levy, G.A., Rotstein, O.D. Induction of macrophage procoagulant activity by murine hepatitis virus strain 3: Role of tyrosine phosphorylation. *Journal of Virology*, 1995;69(8), September.
102. Wanless, I.R., Wong, F., Blendis, L.M., Greig, P.D., Heathcote, E.J., Levy, G.A. Role of hepatic and portal vein thrombosis in cirrhosis: Possible role for development of parenchymal extinction and portal hypertension. *Hepatology*, 1995;21(5):1238-47.
103. Camargo, Jr. C.A., Greig, P.D., Levy, G.A., Clavien, P.A. Acute pancreatitis following liver transplantation. *Journal of the American College of Surgeons*, 1995;181:249-56.
104. Cattral, M., Rezieg, M., Greig, P., Cole, E., Cameron, R., Krajden, M., Phillips, M.J., Levy, G.A. A pilot study of Ribavirin for the treatment of post transplant hepatitis C. *Transplantation*, 1996;61(10):1483-1488 [May]
105. Peltekian, K., Makowka, L., Williams, R., Blendis, L., Levy, G. Prostaglandins in liver failure and transplantation: Regeneration, immunodulation and cytoprotection. *Liver Transplantation and Surgery*, 1996;2(3):171-184 [May]
106. Treatment of Chronic Viral Hepatitis with Alpha Interferon: A Consensus Conference Report. *Can. J. Gastro.* 1996;10(1):21-25 [Jan/Feb].
107. Yuwaraj, S., Cattral, M., Pope, M., Levy, G. Murine hepatitis virus - Molecular biology and pathogenesis. *Viral Hepatitis Reviews*, 1996;2(2) [July]
108. M.J. Phillips, C.A. Ackerley, R. Superina, M. Filler, G.A. Levy. Excess zinc associated with severe progressive cholestasis in Cree and Ojibwe-Cree children. *Lancet*, 347:866-868:1996 [March]
109. Pope, M., Chung, S., Mosmann, T., Leibowitz, J., Gorczynski, R., Levy, G.

Resistance of naive mice to murine hepatitis virus strain 3 (MHV-3) requires development of a Th1, but not Th2 response, whereas pre-existing antibody protects against primary infection. *Journal of Immunology*, 1996;156(9):3342-3349 [May]

110. Clavien, P.A., Camargo, C.A., Cameron, R., Washington, M.K., Phillips, M.J., Greig, P.D. Levy, G.A. Kupffer cell erythrophagocytosis and graft-versus-host hemolysis in liver transplantation. *Gastroenterology*, 1996;110-1891-1896 [June]
111. Clavien, P.A., Camargo, C.A., Gorczynski R., Washington, M.K., Levy, G.A., Langer, B., Greig, P.D. Acute reactant cytokines and neutrophil adhesion after warm ischemia in cirrhotic and non-cirrhotic human livers. *Hepatology*, 1996;23(6):1457-1463 [June]
112. Fingerote, R., Abecassis, M., Pope, M., Phillips, M.J., Rao, Y.S., Cole, E.H., Leibowitz, J., Levy, G.A. Loss of resistance to murine hepatitis virus strain 3 (MHV-3) infection following infection with corticosteroids is associated with induction of macrophages procoagulant activity (PCA). *Journal of Virology*, 1996;70(7):4275-4282 [July]
113. Hemming, A.W., Greig, P.D., Cattral, M.S., Chung, S.W., Lilly, L.B., Aljumah, A.A., Levy, G.A. Neoral without intravenous cyclosporine in liver transplantation. *Transplantation*, 1996;62:1798-1802 [Dec]
114. Hemming, A.W., Levy, G.A. Neoral conversion in stable liver transplantation recipients. *Transplantation & Immunology Letter*. 1996;12:4-13.
115. Littlefield, C., Abbey, S., Fiducia, D., Cardella, C., Greig, P., Levy, G., Maurer, J., Winton, T. Quality of life following transplantation of the heart, liver and lungs. *General Hospital Psychiatry*. 1996;18:36S-47S.
116. Gorczynski, R.M., Adams, R.B., Levy, G.A., Chung, S.W. Correlation of peripheral blood lymphocyte and intra-graft cytokine mRNA expression with rejection in orthotopic liver transplantation. *Surgery* 1996;120(3):496-502 [September]
117. Gorczynski, R.M., Cohen, Z., Levy, G., Fu, X.M. A role for gamma (delta) TCR+ cells in regulation of rejection of small intestinal allografts in rats. *Transplantation*. 1996;62(6):844-5.
118. Sullivan, B., Cohen, Z., Fu, X.M., Levy, G., Plapler, H., Wojcik, D., Gorczynski, R.M. Graft infiltrating cells in rats receiving orthotopic semiallogeneic small intestine transplantation with portal or systemic venous drainage. *Transplantation*. 1996;62(6):715-21.

Gary A. Levy, MD

119. Chung, S.W., Greig, P.D., Cattral, M.S., Taylor, B.R., Sheiner, P.A., Cameron, R., Phillips, M.J., Blendis, L.M., Langer, B., Levy, G.A. Liver transplantation: An evaluation of high risk indications. *British Journal of Surgery*, 84:189-195:1997. [March]
120. McGilvray, I., Lu, Z., Dackiw, A., Levy, G., Rotstein, A. Differential activation of the p38 and ERK MAP kinases by MHV-3. *Surgical Forum*. 1997:48:188-191.
121. Shepherd, F.A., Maher, E., Cardella, C., Cole, E., Greig, P.D., Levy, G.A. Treatment of Kaposi's sarcoma after solid organ transplantation. *Journal of Clinical Oncology*, 15(6):2371-2377:1997[June].
122. Levy, G., Rasmussen, A., Mayer, A.D., Jamieson, N.V., Neuhaus, P. Neoral in denovo liver transplantation: Adequate immunosuppression without intravenous cyclosporine. *Liver Transplantation and Surgery*, 3(6)[November]:571-77:1997.
123. Ding, J.W., Ning, Q., Liu, M., Lai, A., Peltekian, K.M., Fung, L.S., Holloway, C., Marsden, P.A., Yeger, H., Cole, E.H., Phillips, M.J., Levy, G.A. Fulminant hepatic failure in murine hepatitis virus strain 3 (MHV-3) infection: Tissue-specific expression of a novel prothrombinase fgl2. *Journal of Virology*, 2(2):125-142, 1997.
124. Ning, Q., Brown, D., Parodo, J., Cattral, M., Gorczynski, R., Cole, E.H., Fung, L.S., Ding, J.W., Liu, M.F., Rotstein, O., Phillips, M.J., Levy, G.A. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves Th1 cytokine production, but inhibits Th2 cytokine response. *Journal of Immunology*, 160(7):3487-93:1998.[April]
125. Chung, S.W., Gould, B., Zhang, R., Hu, Y., Levy, G.A., Gorczynski, R.M. Pretreatment of donor stimulator cells by 16, 16 dimethyl prostaglandin E₂ influences the recipient immune response. *Surgery* 1998:123(2):171-80.
126. Clark, D., Chaouat, G., Arck, P.C., Mittruecker, H.W., Levy, G.A. Cytokine-dependent abortion in CBA x DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase. *Journal of Immunology*, February 15, 160:545-49, 1998.
127. Hemming, A., Cattral, Chari, R.S., M.S., Greig, P.D., Lilly, L.B., Ashby, P., Levy, G.A. Domino liver transplantation for familial amyloid polyneuropathy. *Liver Transplantation and Surgery*, May 1998, 4(3):236-238.
128. Pope, M., Marsden, P.A., Cole, E., Sloan, S., Fung, L.S., Ning, Q., Ding, J.W., Leibowitz, J.L., Phillips, M.J., Levy, G.A. Resistance to murine hepatitis virus strain 3 is dependent on production of nitric oxide. *J. Virology*,

[September]1998, 72(9):7084-7090.

129. Liu, M.F., Ning, Q., Pope, M., Mosmann, T., Leibowitz, J., Ding, J.W., Fung, L.S., Rotstein, O., Gorczynski, R., Levy, G.A. Resistance of naive mice to murine hepatitis virus strain 3 requires development of a Th1, but not a Th2 response, whereas pre-existing antibody partially protects against primary infection. *Advances in Experimental Medicine and Biology*, 1998:440:415-423 (September).
130. Ding, J.W., Ning, Q., Liu, M.F., Lai, A., Phillips, M.J., Peltekian, K., Fung, L.S., Holloway, C., Levy, G.A. Expression of the fgl2 gene and its protein product (prothrombinase) in tissues during murine hepatitis virus strain 3 (MHV-3) infection. *Advances in Experimental Medicine and Biology*, 1998:440:609-618 (September).
131. Belyavskiy, M., Levy, G.A., Leibowitz, J.L. The pattern of induction of apoptosis during infection with MHV-3 correlates with strain variation in resistance and susceptibility to lethal hepatitis. *Advances in Experimental Medicine and Biology*, 1998:440:619-625 (September).
132. Hemming, A.W., Cattral, M.S., Greig, P.D., Meisner, J., Turcotte, L., Lilly, L.B., Levy, G.A. A pharmacoeconomic analysis of Neoral without intravenous cyclosporine in liver transplantation in Canada. *Clinical Transplantation*. 1998;12(5):425-429 (October).
133. Belyavskiy, M., Belyavskaya, E., Levy, G.A., Leibowitz, J.L. Coronavirus MHV-3 induced apoptosis in macrophages. *Virology*, 1998:250:41-49 [November].
134. McIlvray, I., Rotstein, O.D., Levy, G.A. et. al. MHV-3 induces the macrophage prothrombinase fgl2 through p38 map kinase activation. *Journal of Biological Chemistry*, [November] 1998:273(48):32222-32229.
135. Roy, A., Grant, D.R., Kneteman, N.M., Tchervenkova, J. I., Levy, G.A., Tan, A., Hendricks, L. A comparative randomized prospective multicenter study of Sandimmune vs. Neoral in liver transplantation. *Ann Chir.* 1998;52(8):716-71.
136. Gorczynski, R.M., Cattral, M., Greig, P., Levy, G.A., Sun, Y. and Chung, S.W. Donor-specific restimulation in vitro of peripheral blood lymphocytes (PBL) from recipients of orthotopic liver grafts is associated, in the absence of rejection, with type-2 cytokine production. *Immunol. Letters* 1998;63(2):91-96 [September].
137. Bigham, D., Zhong, R., Levy, G.A., Grant, D. Xenotransplantation. *Canadian Journal of Surgery*, 1999:42(1):12-16 [February].

138. Ning, Q., Kongkham, P., Liu, M.F., Lai, M., Levy, G.A. Nucleocapsid gene of murine hepatitis virus strain 3 (MHV-3) induces transcription of the fgl2 prothrombinase gene. *J. Biol. Chem.* 1999;274(15):9930-6. [April]
139. Grant, D., Kneteman, N., Roy, A., Tchervenkov, J., Levy, G.A. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: Results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8). *Transplantation*, 1999;67(8):1133-1137 [April].
140. Sim, H., Marinov, A., Levy, G.A. Xenotransplantation: A Potential Solution to the Critical Organ Donor Shortage. *Canadian Journal of Gastroenterology*, [May] 1999;13(4):311-318.
141. Perrillo, R., Rakela, J., Dienstag, J., Levy, G.A., Martin, P. et. al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. *Hepatology*. [May] 1999;29;1581-1586.
142. Cattral, M.S., Hemming, A.W., Wanless, I.R., Al Ashgar, H., Krajden, M., Lilly, L, Greig, P.D., Levy, G.A. Outcome of long-term Ribavirin therapy for recurrent hepatitis C after liver transplantation. *Transplantation*. [May] 1999;67(9);1277-80.
143. Yang, L, DuTemple, B., Gorczynski, R.M., Levy, G.A., Zhang, L. Evidence for epitope spreading and active suppression in skin graft tolerance following donor specific transfusion. *Transplantation*, 1999;67:1404-1410. [June].
144. Clark, D.C., Ding, J.W., Chaouat, G., Coulam, C.B., August, C., Levy, G.A. The Emerging Role Of Immunoregulation Of Fibrinogen-Related Procoagulant Fgl2 In The Success Or Spontaneous Abortion Of Early Pregnancy In Mice And Humans. *American Journal of Reproductive Immunology*, 1999;42(1)37-43. [July]
145. Levy, G.A. Neoral/cyclosporine-based immunosuppression. *Liver Transplantation and Surgery*, 1999;5(4 suppl 1):S37-S47 [July].
146. Hyman, A., Yim, C., Krajden, M., Read, S., Basinski A, Wanless, I., Levy, G. and Heathcote, J. Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C. *J. Viral Hepatitis*. 1999;6:329-336. [August]
147. Perampalam, S., Wang, L., Myers-Mason, N., Stanietsky, N., Weitz, J.I., Phillips, M.J., Ackerley, C., Levy, G.A, Cole, E. Identification of a unique glomerular factor X activator in murine lupus nephritis. *J Am Soc Nephrol*. 1999 Nov;10(11):2332-41.
148. Humar, A., Gregson, D., Caliendo, A.M., McGeer, A., Malkan, G., Krajden, M.,

- Corey, P., Greig, P., Walmsley, S., Levy, G., Mazzulli, T. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. *Transplantation*, 1999;68(9):1305-11 [November]
149. Levy, G.A. Liu, M.F., Ding, J.W., Yuwaraj, S., Leibowitz, J.L., Marsden, P., Ning, Q., Kovalinka, A., Phillips, M.J. Molecular and functional analysis of the human prothrombinase gene (h-fgl2) and its role in viral hepatitis. *American Journal of Pathology*, 156(4):1217-1225, April, 2000.
 150. Malkan, G., Cattral, M.S., Humar, A., Alashgar, H., Greig, P.D., Hemming, A.W., Levy, G.A., Lilly, L.B. Lamivudine for hepatitis B in liver transplantation. *Transplantation*. 69(7):1403-1407, 2000 [April].
 151. Bigam, D.L., Pennington, J.J., Carpentier, A., Hemming, A.W., Croxford, R., Greig, P.D., Lilly, L.B., Heathcote, E.J., Levy, G.A. and Cattral, M.S. Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplanted. *Hepatology* 32(1):87-90, 2000.[July]
 152. Belitsky, P., Dunn, S., Johnston, A. Levy, G. Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. *Clinical Pharmacokinetics*. 39(2):117-125, 2000 [August]
 153. Humar, A., Malkan, G., Moussa, G., Greig, P., Levy, G., Mazzulli. Human herpes virus-6 is associated with cytomegalovirus reactivation in liver transplant recipients. *Journal of Infectious Diseases, J Infect Dis* 2000 Apr;181(4):1450-3.
 154. Cattral, M.S, Lilly, L.B Levy, G.A., Immunosuppression in Liver Transplantation. *Seminars in Liver Disease*, 20(4):523-531, 2000. [November].
 155. Lilly, L.B., Cattral, M.S., Levy, G.A. Hepatitis C and Liver Transplantation. *Viral Hepatitis Reviews*. 6(1-4):151-163, 2000 [Dec].
 156. Levy, G.A., Grant, D., Paradis, K., Campestrini, J., Smith, T. and Kovarik, J.M. Pharmacokinetics and tolerability of 40-0-[2-Hydroxyethyl] Rapamycin in de novo liver transplant recipients. *Transplantation*, 71(1):160-63, 2001 [January].
 157. Perrillo, R.P., Wright, T., Rakela, J., Levy, G., Schiff, E., Gish, R., Martin, P., Dienstag, J., Adams, P., Dickson, R., Anschuetz, G., Bell, G., Condreay, L., Brown, N. and the Lamivudine North American Transplant Group. *Hepatology*. 33:424-432, 2001 [February]
 158. Yuwaraj, S., Ding, J.W., Liu, M.F., Marsden, P., Levy, G.A. Genomic Characterization, Localization, And Functional Expression Of *Fgl2*, The Human

- Gene Encoding Fibroleukin: A Novel Human Procoagulant, *Genomics*. 71:330-338, 2001 [March].
159. Clark, D.A., Ding, J.W., Yu, G., Levy, G.A., Gorczynski, R.M. Fgl2 prothrombinase expression in mouse trophoblast and decidua triggers abortion but may be countered by OX-2. *Molecular Human Reproduction*. 7(2):185-194, 2001 [February]
 160. Liu, M.F., Chan, C.W., Y., McGilvray, I.D., Phillips, M.J., Ning, Q., Levy, G.A. Fulminant viral hepatitis: molecular and cellular basis, and clinical implications. *Expert Reviews in Molecular Medicine*. 28 March 2001, pages 1-18.
 161. Wiesner R, Rabkin J, Klintmalm G, McDiarmid S, Langnas A, Punch J, McMaster P, Kalayoglu M, Levy G, Freeman R, Bismuth H, Neuhaus P, Mamelok R, Wang WA randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. *Liver Transpl*. 2001 May;7(5):442-50.
 162. Clark, D.A., Yu, G., Levy, G.A., and Gorczynski, R.M. Procoagulants in fetus rejection: role of the OX-2 (CD-200) tolerance signal. *Seminars in Immunology*. 13:4:255-263, 2001 [August].
 163. Knackstedt, M., Ding, J.W., Johnson, N., Arck, P.C., Hertwig, K., Coualam, C.B., August, C., Lea, R., Dudenhausen, J.W., Gorczynski, R.M., Levy, G.A., Clark, D.A. Activation of the novel prothrombinase, fgl2 as a basis for the pregnancy complications spontaneous abortion and pre-eclampsia. *American Journal of Reproductive Immunology*. 46:3:196-210, 2001 [September].
 164. Levy, G.A. Long term immunosuppression and drug interactions. *Liver Transplantation*, 7(11 suppl 2):S53-9, 2001 [November].
 165. Levy, G.A. C2 monitoring strategy for optimising cyclosporin immunosuppression for the Neoral formulation. *Bio Drugs*. 15(5):279-90, 2001.
 166. Humar A, Kumar D, Caliendo AM, Moussa G, Ashi-Sulaiman A, Levy G, Mazzulli T. Clinical impact of human herpesvirus 6 infection after liver transplantation. *Transplantation*. Feb 27;73(4):599-604, 2002.
 167. Luo Y, Levy G, Din J et al. hDAF transgenic pig livers are protected from hyperacute rejection during ex vivo perfusion with human blood. *Xenotransplantation*, 9:36-44, 2002 [March]
 168. G. Levy, P. Burra, A. Cavallari, C. Duvoux, J. Lake, A.D. Mayer, S. Mies, S.G. Pollard, E. Varo, F. Villamil, A. Johnston. Improved clinical outcomes for liver transplant recipients using Cyclosporine monitoring based on 2-hr post-dose levels (C2). *Transplantation*, 73(6): 953-959, 2002 [March]

169. Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. *Clin Ther* 2002 Mar;24(3):330-50; discussion 329
170. G. Levy. New strategies to optimize clinical outcomes with cyclosporine in liver transplantation. *Gastroenterol Hepatol*, Apr;25(4):289-9, 2002.
171. Chan, C.W.Y., Chan, M., Liu, M., Fung, L., Cole, E.H., Yuwaraj, S., Leibowitz, J.L., Marsden, P.A., Clark, D. and Levy, G.A. Kinetic analysis of a unique direct prothrombinase, fgl2, and identification of a serine residue critical for the prothrombinase activity, *J. Immunology*, 168:5170-5177, 2002 [May 15].
172. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, Mazzulli T. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. *Am J Transplant* 2002 May;2(5):461-6.
172. Levy, G.A. and Marsden, P. Cigarette Smoking – Association with Hepatic Artery Thrombosis. *Liver Transplantation*, 8(7):588-90, 2002. [July]
173. Levy G, Thervet E, Lake J, Uchida K; The Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group Patient management by Neoral C(2) monitoring: an international consensus statement. *Transplantation* 15;73(9 Suppl):S12-8, 2002 [May]
174. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C(2) monitoring: a review. *Transplantation* May 15;73(9 Suppl):S3-11, 2002.
175. Levy G, Thervet E, Lake J, Uchida K; The Consensus on Neoral C(2): Expert Review in Transplantation (CONCERT) Group Patient management by Neoral C(2) monitoring: an international consensus statement. *Transplantation* May 15;73(9 Suppl):S12-8, 2002.
176. Ghanekar, A., Lajoie, G., Luo, Y., Yang, H., Choi, J. et al. Improvement in rejection of human decay accelerating factor transgenic pig-to-primate renal xenografts with administration of rabbit anti-thymocyte serum (RATS). *Transplantation*, July 15, 74:28-35, 2002.
177. Zhong R., Luo Y., Yang H., Garcia B., Ghanekar A., Luke P., Chakrabarti S., Lajoie G, Phillips, M.J., Katopodis A.G., Duthaler R.O., Catral M., Wall W., Jevnikar A., Bailey M., Levy, G.A., Grant D.R. Improvement In Hdaf Transgenic Porcine Kidney Xenograft Rejection With Intravenous Administration Of Gas 914, a polymeric form of α GAL. *Transplantation* 2003 Jan 15;75(1):10-9.

178. Q. Ning, L. Berger, X. Luo, W. Yan, J. Dennis, G.A. Levy. STAT1 and STAT3 α/β Splice Form Activation Predicts Host Responses in Mouse Hepatitis Virus Type 3 Infection. *J Med Virol* 2003 Mar;69(3):306-12.
179. Johnson, A., Levy, G.A. The TMC Study. *Lancet* 2003 Jan 25;361(9354):346-7.
180. Levy GA. The development and application of C2 monitoring in liver transplantation. *Transplantation and Immunology Letters*, 18(1), 2003 in press.
181. C. W.Y. Chan, M.W.C. Chan, L. Zhang, R.M. Gorczynski, and G.A. Levy. Soluble fgl2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and preventing final maturation of bone marrow-derived dendritic cells, *Journal of Immunology*, Apr 15;170(8):4036-44, 2003.
182. David A. Clark, Gary Yu, Gary A. Levy, Reginald Gorczynski. MD-1 is a critical part of the mechanism causing Th1-cytokine-triggered murine fetal loss syndrome. *Am J Reprod Immunol.*, 49:297-307, 2003.
183. Q. Ning, S. Lakatoo, , M. Liu, M.J. Phillips, P.S. Masters, M.M.C. Lai, P.A. Marsden, J. Leibowitz, G.A. Levy. Induction of prothrombinase fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 α , *Journal of Biological Chemistry*, in press 2003.
184. Mingfeng Liu, Julian L. Leibowitz, Jin Wen Ding, Qin Ning, Laisum Fung, Phillip Marsden, Gary Levy. Transcriptional Regulation of the Murine fgl2 Prothrombinase: Contribution of Sp1, Variants of Sp3, Ets Family Members and Stat3-like protein. *European Journal of Biochemistry*, in press, 2003.
185. Phillips, M.J., Azuma, T., Meredith, S-L. M., Squire, J.S., Ackerley, C.A., Pluthero, F.G., Roberts, E.A., Superina, R.A., Levy, G.A., Marsden, P.A. A progressive cholestatic liver disease of childhood with abnormalities in villin gene expression and canalicular microvillus structure. *Lancet*, in press, 2003.
186. P. Marsden, L.S. Fung, M. Mendicino, A. Ghanekar, T. Miller, C. Chan, M. Chan, W. He, R.M. Gorczynski, D. Grant, D.A. Clark, M.J. Phillips, G.A. Levy. The Fgl2/fibroleukin prothrombinase contributes to immunologically-mediated thrombosis in viral hepatitis and xenotransplantation, in press, 2003 *J. Clin. Invest.*

B. Submitted or in Preparation

1. A. Ghanekar, Muradali, D, Wilson, S., Lajoie, G., Phillips, M.J., Levy, G.A., Grant, D.R. Shared sonographic characteristics of rejecting human kidney allografts and pig-to-primate kidney xenografts, submitted, *AJR* January 2003.

Gary A. Levy, MD

2. Clark, D.A., Fung, L.S., Marsden, P.A., Lee, L., Mendicino, M., Gorczynski, R.M., Phillips, M.J., Levy, G.A. The Fgl2 Prothrombinase/Fibroleukin Gene Is Required For Lps-Triggered Abortions And For Normal Hemostasis During Murine Reproduction. *American Journal of Reproductive Immunology*.
3. Mendicino, M., He, W., Fung, L.S., Marsden, P., Grant, D., Phillips, M.J., Levy, G.A. FGL-2^{-/-} cardiac xenografts lack thrombosis but undergo a novel accelerated cellular immune response.
4. L.E. Marra, Z.X. Zhang, G.A. Levy, J. Penninger, and L. Zhang: IL-10 inhibits the function of antigen-specific regulatory cells by enhancing their susceptibility to apoptosis. To be submitted to *J .Exp. Med.*, 2003

C. Proceedings

1. Abecassis, M., Falk, J., Makowka, L., Dindzans, L., Falk, R., Levy, G.A. Cyclosporin A (CsA) fails to alter innate resistance to murine hepatitis virus strain 3 (MHV-3) infection in A/J mice. *Transplantation Proceedings*. 19:1214-1217;1987.
2. Abecassis, M., Falk, J., Makowka, L., Dindzans, L., Falk, R., Levy, G.A. Prostaglandin E2 (PGE2) prevents fulminant hepatitis and the induction of procoagulant activity (PCA) in susceptible animals. *Transplantation Proceedings*. 19:1103-1105;1987.
3. Wong, P.Y., Mason, N., Cheung, F., Abecassis, M., Mee, A.V., Cole, E.H., Dindzans, V.J., Langer, B., Makowka, L., Cohen, Z., Van Thiel, D., Levy, G.A. Cyclosporine metabolites suppress T cell proliferation induced by concanavalin A. *Transplantation Proceedings*. 19:2588;1987.
4. Cohen, Z., Silverman, R., Levy, G.A., Wassef, R., Langer, B. Clinical small intestinal transplantation using cycloporin A (CsA) and methylprednisolone. *Transplantation Proceedings*. 19:2588-2590;1987.
5. Cole, E.H., Skorecki, K., Wong, P.Y., Fung, L.S., Levy, G.A. Cyclosporin A in contrast to cyclosporine metabolite (OL-17) specifically inhibits growth of renal cells in culture. *Transplantation Proceedings*. 20:732-737;1987.
6. Wu, T., Au, J.X., Greig, P.D., Strasberg, S.M., Ettles, M., Abecassis, M., Superina, R.A., Langer, B., Blendis, L., Taylor, B.R., Phillips, M.J. and Levy, G.A. Conjugated and delta bilirubin determinations in early liver allograft rejection. *Transplantation Proceedings*. 20:393-398;1987.
7. Cheung, F., Wong, P.Y., Loo, J., Cole, E.H., Levy, G.A. Identification of

Gary A. Levy, MD

cyclosporine metabolites in human bile, blood and urine by HPLC/RIA/FABMS. Transplantation Proceedings. 20:479-483;1988.

8. Cheung, F., Wong, P.Y., Cole, E.H., Cohen, Z., Levy, G.A. Generation and characterization of cyclosporine metabolites produced in a hepatic microsomal system. Trans. Proc. 20:510-515;1988.
9. Superina, R., A., Pearl, R., Greig, P., Levy, G., Falk, J., Langer, B. Effect of DRw6 antigen in recipients and donors on survival after liver transplant. Trans. Proc. 21:3360-3361;1989.
10. Greig, P., Woolf, G., Blendis, L., Abecassis, M., Falk, R., Levy, G.A. Prostaglandin E1 treatment for primary non-function after liver transplantation. Trans. Proc. 21:3360-3361;1989.
11. Gallinger, S., Blendis, L., Levy, G., Roberts, E., Superina, R., Langer, B., Greig, P. Liver transplantation for acute and subacute fulminant hepatic failure. Trans. Proc. 21:2435-2438;1989.
12. Greig, P.D., Superina, R., Blendis, L., Taylor, B., Langer, B., Levy, G. Antilymphoblast globulin (ALG) as initial prophylaxis against rejection following liver transplantation. Trans. Proc. 21:2244-2246;1989.
13. Forester, J., Superina, R.A., Levy, G., Glynn, M.F.X., Poon, A., Greig, P. Coagulation factors as indicators of early function following liver transplantation. Trans. Proc. 21:2308-2310;1989.
14. Kim, P., Wakefield, A.J., Cohen, Z., Craig, M., Levy, G. Reversal of cyclosporin A mediated suppression of allogeneic induced monocyte procoagulant activity by H2 antagonists. Trans. Proc. 21:2900-2902;1989.
15. Kim, P., Wakefield, A.J., Craig, M., Cohen, Z., Levy, G. Reversal of cyclosporin A mediated suppression of allogeneic induced monocyte procoagulant activity by H2 antagonists in vitro. Trans. Proc. 21:844;1989.
16. Cole, E.H., Fung, L., Cheung, F., Wong, P.Y., Skorecki, K., Levy, G. Toxic effects on renal cells in culture. A comparison of cyclosporin A and its metabolites. Trans. Proc. 21:943;1989.
17. Greig, P.D., Woolf, G.M., Forester, J., Strasberg, S.M., Taylor, B., Superina, R.A., Glynn, M.F.X., Ettles, M., Blendis, L., Levy, G.A. Prostaglandin E1 for primary non-function following liver transplantation. Trans. Proc. 21:2385-2388;1989.
18. Forster, J., Greig, P.D., Glynn, M.F.X., Poon, A., Levy, G.A., Superina, R.A., Langer, B. Predictors of graft function following liver transplantation. Trans. Proc. 21:3356-3357;1989.

Gary A. Levy, MD

19. Levy, G.A., Sherker, A., Fung, L.S., Greig, P.D., Sherman, M., Blendis, L.M. Relevance of hepatitis B viral DNA (HBV DNA) in assessment of potential liver allograft recipients. *Trans. Proc.* 21:3333-3334:1989.
20. Greig, P.D., Forster, J., Superina, R.A., Strasberg, S.M., Mohamed, M., Taylor, B.R., Levy, G.A., Langer, B. Donor-specific factors predict graft function following liver transplantation. *Trans. Proc.* 1989:22(4):2072-73.
21. Kim, P., Cohen, Z., Wong, P.Y., Levy, G.A. Immunologic basis of small intestinal allograft rejection. *Trans. Proc.* 1990:23(1):830-832.
22. Koh, I., Kim, P., Chung, S., Oziel, P., Fung, L., Waddell, T., Levy, G., Cohen, Z. Effects of 16,16 dimethyl prostaglandin E2 alone and in combination therapy with low dose cyclosporin A rat small intestinal transplantation. *Trans. Proc.* 1992:23(3):1164-1165.
23. Gorczynski, R., Cohen, Z., Levy, G., Koh, I. Comparison of functional activity in host and graft mesenteric lymphoid tissue of rats receiving syngeneic heterotopic SBT with portal or systemic drainage. *Trans. Proc.* 1992:24(3):1133-34.
24. Koh, I., Cohen, Z., Levy, G., Gorczynski, R.M. Altered cell trafficking in mesenteric lymphoid tissue following syngeneic heterotopic small bowel transplantation in rodents. *Trans. Proc.* 1992:24(3):1146-7.
25. Koh, I., Cohen, Z., Levy, G., Plapler, H., Gorczynski, R.M. Altered cell trafficking of mesenteric lymphocytes after heterotopic small bowel transplantation using systemic venous drainage. *Trans. Proc.* 1993:25(1):1210-1211.
26. Paul, A., Levy, G., Greig, P.D. Balancing cyclosporin A nephrotoxicity and rejection late after adult liver transplantation. *Trans. Proc.* 1993:25(4):2664-5.
27. Paul, A., Superina, R.A., Levy, G.A., Greig, P.D. Can split liver grafting increase the overall success rate of liver transplantation. *Trans. Proc.* 1993:25(4):2620-21.
28. Wojcik, D., Cohen, Z., Fu, X.M., Plapler, H., Levy, G., Gorczynski, R. Graft-infiltrating cells in SIT of rats with portal or IVC drainage. *Trans. Proc.* 1994:26(3):1578.
29. Elkashab, M., Rezieg, M., Greig, P.D., Cameron, R., Phillips, M.J., Levy, G. Incidence and patterns of rejection using different induction therapies in liver transplant recipients. *Trans. Proc.* 1994:26(5):2669-71 (October)

30. Levy, G.A. and Grant, D. The potential for Neoral in liver transplantation. Trans. Proc. 1994:26(5):2932-34 (October)
31. Levy, G.A., Rochon, J., Freeman, J., Wong, P.Y., Banks, L., Roach, C., Engel, K., Grant, D. Cyclosporine Neoral in liver transplant recipients. Trans. Proc. 1994:26(5):2949-2952 (October)
32. Gorczynski, R.M., Cohen, Z., Fu, X.M., Levy, G.A., Sullivan, B., Plapler, H. Hepatic regulation of lymphocyte:endothelial cell interaction. Trans. Proc. 1994:26(3):1623 (October)
33. Chen, M., Wade, J., Levy, G.A., Greig, P.D. Effect of HLA matching on T and B cell crossmatch on acute rejection and graft survival following liver transplantation. Trans. Proc. 1994:26(5):2695-96 (October)
34. Duncan, S., Liu, W.T., Levy, G.A., Skorecki, K., Pang, H., Wong, P.Y. Isolation and identification of two cyclosporine aldehydic metabolites from the bile of a liver transplant recipient during an acute nephrotoxic episode. Trans. Proc. 1994:26(5):2899-2901 (October)
35. Levy, G.A., Grant, D. Neoral in liver transplantation. Trans. Proc. 1996:28(2):1019-20 (April)
36. Levy, G.A. The new cyclosporine formulation for microemulsion: Extending the therapeutic horizon. Trans. Proc. 1996:28.
37. Aljumah, A.A., Cattral, M.S., Greig, P.D., Krajden, M., Hemming, A.W., Lilly, L.B., Levy, G.A. Longterm Ribavirin therapy after recurrent hepatitis C after liver transplantation. Trans. Proc. 1997:29:514 (February)
38. Hemming, A., Greig, P.D., Cattral, M.S., Chung, S.W., Lilly, L.B. Neoral without intravenous cyclosporine in liver transplantation. Transp. Proc. 1997:29:543 (Feb)
39. Philosophe, B., Hemming, A.W., Cattral, M.S., Chung, S.W., Lilly, L.B., Levy, G.A., Greig, P.D. Late graft loss following liver transplantation. Trans. Proc. 1997:29:363-364 (February)
40. Gorczynski, R., Chen, M., Levy, G.A. $\gamma\delta$ TCR+, Type 2 cytokine produced by hybridoma cells produced in mice given portal vein pretransplant immunization and allogeneic grafts can increase graft survival on adoptive transfer. Trans. Proc. 1997:29:865-866 (February)

41. Canadian Liver Transplant Group. Importance of cyclosporine pharmacokinetics to clinical outcomes after liver transplantation. *Transplant Proceedings*, 1998;30:1826 (August).
42. Levy, G.A., Marsden, P., Zhong, R., Cole, E.H., Grant, D. Strategies to prevent thrombosis in xenotransplant. *Transplant Proceedings*, 1998;30:2458-60 (August).
43. Levy, G.A. Neoral is superior to FK506 in liver transplantation. *Transplant Proceedings*, 1998;30:1812-1815 (August).
44. Keown, P., Kahan, B.D., Johnston, A., Levy, G., Dunn, S.P., Cittero, F., Grino, J.M., Hoyer, P.F., Wolf, P., Halloran, P.F. Optimization of Cyclosporine therapy with new therapeutic drug monitoring strategies. *Transplant Proceedings*, 1998;30(5):1645-49.(August)
45. Cattral, M.S., Hemming, A.W., Greig, P.D., Roswell, C., Chari, R., Cole, E., Donat, D., Wright, E., Levy, G.A. Outcome of kidney transplant alone versus synchronous pancreas-kidney transplantation in type I diabetics. *Transplant Proceedings*, 1998;30(5):1938-39.(August)
46. Cattral, M.S., Hemming, A.W., Greig, P.D., Roswell, C., Chari, R., Wright, E., Donat, D., Cole, E., Levy, G.A. Low incidence of rejection after synchronous pancreas-kidney transplantation with Neoral. *Transplant Proceedings*, 1998;30(5):1946.(August)
47. Levy, G.A. Relationship of pharmacokinetics to clinical outcomes. *Transpl. Proc.* 1999;31(3):1654.
48. Zhang, L., DuTemple, B., Yang, L., Phillips, M.J., Levy, G.A., Zhang, Z.X. Blocking development of lymphoma in the absence of GVHD by infusion of allogeneic splenocytes. *Proceedings of the 10th International Congress in Immunology*, Talwar, G.P., Nath, I., Ganguly, N.K, Rao, K.V.S. eds. 1515-1519:1999. [January]
49. Gorczynski, R.M., Levy, G., Chen, Z. Hepatic mononuclear cells modulate delivery of immunogenic stimuli by allogeneic dendritic cells. *Trans. Proc.* 1999;31:856-857 [February/March].
50. Hemming, A.W., Cattral, M.S., Greig, P.D., Lilly, L.B., Ashby, P., Levy, G.A. Domino liver transplantation for familial amyloid polyneuropathy: Optimal use of a scarce resource. *Trans. Proc.* 1999;31:515 [February/March].
51. Levy, G.A. Neoral use in the liver transplant recipient. *Transplant Proc.* 2000 May;32(3A Suppl):2S-9S.

52. Belitsky, P., Levy, G.A. and Johnston, A. Neoral-absorption profiling: an evolution in effectiveness. *Transplantation Proceedings*, 32(3A), 45S-52S, 2000.
53. Malkan, G, Humar A, Lilly LB, Greig PD, Grant DR, Wanless IR, Cameron R, Hemming AW, Levy GA, Cattral MS. Natural history of recurrent hepatitis C after liver transplantation, submitted, *Trans. Proc.* 33(1-2):1468, 2001 [March].
54. Young KJ, DuTemple B, Zhang Z, Levy G, Zhang L. CD4(-)CD8(-) regulatory T cells implicated in preventing graft-versus-host and promoting graft-versus-leukemia responses. *Transplant Proc.* 2001 Feb-Mar;33(1-2):1762-3
55. Levy, G.A., Ghanekar, A., Mendicino, M., Phillips, M.J., Grant, D.R. The present status of xenotransplantation. *Transplantation Proceedings*. 2001 Nov-Dec;33(7-8):3050-2.
56. Levy, G.A. Neoral C2 in liver transplant recipients. *Transplantation Proceedings Transplant Proc.* 2001 Nov;33(7-8):3089-91.
57. Ghanekar A, Luo Y, Yang H, Garcia B, Luke P, Chakrabarti S, Lajoie G, Phillips MJ, Katopodis A, Cattral MS, Wall W, Jevnikar A, Bailey M, Levy GA, Grant DR, Zhong R. The alpha-gal analog GAS914 ameliorates delayed rejection of hDAF transgenic pig-to-baboon renal xenografts. *Transplant Proc* 2001 Nov;33(7-8):3853-4.
58. Ghanekar A, Lajoie G, Luo Y, Yang H, Choi J, Garcia B, Greig PD, Cattral MS, Cole EH, Phillips MJ, Cardella CJ, Levy GA, Zhong R, Grant DR. Treatment with rabbit antithymocyte serum permits a cyclophosphamide-free approach to prevention of hDAF transgenic porcine kidney xenograft rejection in baboons. *Transplant Proc* 2001 Nov;33(7-8):3849-50.
59. Levy GA, Ghanekar A, Mendicino M, Phillips MJ, Grant DR. The present status of xenotransplantation. *Transplant Proc* 2001 Nov;33(7-8):3050-2.

D. Reviews and Book Chapters

1. Levy, G.A., Chisari, F.V. The immunopathogenesis of hepatitis B virus induced liver disease: In: *Springer Seminars in Immunopathology*, Springer International. Meischer, P.A., Muller-Eberhard, H.J. eds. Springer-Verlag, New York. 3:32-39:1981.
2. Levy, G.A., Chisari, F.V. A proposed role for the immune system in the pathogenesis of hepatitis B virus induced liver disease. In: *Clinical Reviews in Clinical Laboratory Sciences*. CRC Press, Florida, 15(4):33-35:1981.

Gary A. Levy, MD

3. Levy, G.A., Chisari, F.V. Cellular and molecular interactions responsible for hepatocellular injury in viral hepatitis. In: Recent Progress in Diagnostic Laboratory Immunology. Nakamura, R. ed. Academic Press, San Diego, California, 1981.
4. Edgington, T.S., Levy, G.A., Schwartz, B.S., Fair, D.S. Cellular pathways and requirements for induction of lymphoid procoagulant pathways. In: Advances in Immunopathology, Weigle, W. ed. Elsevier, North Holland. 1981.
5. Edgington, T.S., Schwartz, B.S., Levy, G.A., Fair, D.S. Unidirectional T lymphocyte induction of monocyte procoagulant molecules. In: VIIIth International Symposium on Immunopathology, Kunkel, H. and Dixon, F. eds. Academic Press, New York. pg. 25-55, 1981.
6. Levy, G., Leibowitz, J.L., Edgington, T.S. Lymphocyte instructed monocyte induction of the coagulation pathways parallels the induction of hepatitis by the murine hepatitis virus. In: Progress in Liver Diseases Vol. VII, Popper, H. and Schaffner, F., eds. Grune and Stratton, New York, Chapter 23, page 393, 1982.
7. Dindzans, V., Levy, G.A. Recent advances in the diagnosis and treatment of viral hepatitis. Modern Medicine. March, 1985, p. 2770-2779.
8. Edgington, T.S., Helin, H., Gregory, S.A., Fair, D.S., Levy, G.A., Schwartz, B.S. Cellular pathways and signals for the induction bisynthesis of plasminogen activators in cells of the monocyte lineage. Knook and Wisse eds. Elsevier, North Holland, In: Mononuclear phagocytes, R. Van Furth ed. Martinus Nijhoff, Boston. p. 687-696, 1985.
9. Pappas, S.C., Levy, G., Gordon, V.P., Nakatsukasa, H., Martin, P. The GABA hypothesis of hepatic encephalopathy: Further studies in multiple animal models. Advances in Ammonia and Hepatic Encephalopathy. International Symposium in Ammonia. Elsevier, Amsterdam, p. 340-346, 1988.
10. Woolf, G., Levy, G.A. Chronic viral hepatitis. Modern Medicine 21:3979-90:1988.
11. Levy, G.A. Treatment of viral hepatitis. Drug Protocol. 3:11-16:1988.
12. Cole, E. and Levy, G. Interaction of monocytes with vascular endothelium In: The Human Monocyte, E. Asherson ed. Academic Press, London, England. 8.3:431-437:1989.
13. Levy, G. and Cole, E. The monocyte and disseminated intravascular coagulation In: The Human Monocyte, E. Asherson ed. Academic Press, London, England. 7.1:354-359:1989.

Gary A. Levy, MD

14. Woolf, G., Levy, G.A. Chronic viral hepatitis. *Modern Medical Forum.* 33:4-8:1989.
15. Sheiner, P., Greig, P., Levy, G.A. Perioperative management of the liver transplant patient. *Update in Intensive Care and Emergency Medicine.* J.L. Vincent eds. Springer-Verlag, p. 706-719:1990.
16. Sinclair, S.B., Levy, G.A. Eicosanoids and the liver. *Italian Journal of Gastroenterology.* 22:205-213:1990.
17. Levy, G.A., Sinclair, S.B. Mechanisms of liver injury. In: *Textbook of Liver Disease.* G. Gitnick ed. C.V. Mosby, p. 51-78:1992.
18. Levy, G. Drug induced liver disease. In: *Textbook of Medicine,* W. Kelley ed. J. Lippincott. Philadelphia, PA p. 569-575:1991.
19. Levy, G.A., Chung, S.W., Sheiner, P.A. Approach to the patient with severe liver failure. *Update in Intensive Care and Emergency Medicine.* J.L. Vincent eds. Springer-Verlag, p. 591-597:1991.
20. Sheiner, P., Demajo, W., Levy, G.A. Review of "Acetylcysteine and Fulminant Hepatic Failure". *Hepatology Elsewhere.* 15(3):552-558:1992.
21. Sherker, A., Levy, G.A. New therapeutic strategies for chronic hepatitis in: *Modern Concepts of Gastroenterology.* E. Shaffer ed. Plenum Press, Chapter 14, p. 263-288, 1992.
23. Levy, G.A. and Cole, E.H. Editors, *Procoagulant Activity in Health and Disease.* CRC Press, Boca Raton, Florida. 1993.
24. Fingerote, R.J., Levy, G.A. Pathways for induction and the nature of macrophage procoagulant activity. In: *Procoagulant Activity in Health and Disease.* Levy, G.A. and Cole, E.H. eds. CRC Press, Boca Raton, Florida, p. 3-20:1993.
25. Chung, S.W., Li, C., Leibowitz, J., Levy, G.A. The role of procoagulant activity in fulminant viral hepatitis. In: *Procoagulant Activity in Health and Disease.* Levy, G.A. and Cole, E.H. eds. CRC Press, Boca Raton, Florida, p. 111-130:1993.
26. Levy, G.A. Antibiotic prophylaxis after liver transplants. When and What. *J. Critical Illness.* 9:(1):15-16:1994.
27. Pope, M., Levy, G.A. Congenital malformations of the intra-hepatic biliary tree:

In: Clinical and Surgical Gastroenterology, Coelho, J. ed. MEDSI Editora Medica e Cientifica Ltda., 2:975-984:1995.

28. Levy, G.A., Talbot, P. Editors, Corona- and Related Viruses: Current concepts in molecular biology and pathogenesis. Plenum Press, New York, Advances in Experimental Medicine and Biology, Vol. 380, 1995.
29. Fingerote, R.J., Levy, G.A. Hepatotoxicity of immunomodulating agents. Handbook of Experimental Pharmacology, vol. 121, Cameron R et al (eds). Scientific Publishing Services, Ltd., Springer-Verlag, Heidelberg, Germany, Chapter 24, p. 581-609:1996.
30. Peltekian, K., Levy, G.A. Role of cytokines and immune mechanisms of acute liver failure. In: Acute Liver Failure. Part II: Mechanisms of Disease and Multisystem Involvement. W. Lee and R. Williams eds. Cambridge University Press, Chapter 7, p. 67-78:1997.
31. Lilly, L.B., Hemming, A.W., Levy, G.A. Liver Transplantation, In: First Principles of Gastroenterology. Thomson, A.B.R., Shaffer, E. eds. University of Toronto Press, Toronto, Canada, 1997.
32. Hemming, A.W., Catral, M.S., Greig, P.D., Philosphe, B., Superina, R.A., Lilly, L.B., Levy, G.A.: The University of Toronto Liver Transplant Program. In: Clinical Transplants 1996 (Cecka and Terasaki eds. ULCA Tissue Typing Laboratory). Los Angeles, California, Chapter 13, p. 177-185:1997.
33. Levy, G.A., Murphy, G.F., Keown, P.A. Cyclosporine: Role of Pharmacokinetics. In: Modern Immunosuppressives. H. Schuurman, G. Feutren, J.F. Bach editors. Birkhauser Verlag, Basel, 2001, pp. 11-28.
34. Lilly, L.B., Catral, M.S., Girgrah, N., Humar, A., Greig, P.D., Fecteau, A., Levy, G.A. and Grant, D.: The University of Toronto Liver Transplant Program. In: Clinical Transplants 2000 (Cecka and Terasaki eds. ULCA Tissue Typing Laboratory). Los Angeles, California, Clin Transpl 2000;263-72.
35. Lilly, L.B., Ding, J.W., Levy, G.A. The Immunology of Hepatic Allograft Rejection. In: Transplantation of the Liver, 3rd Edition. W.C. Maddrey, M.F. Sorrell, E.R. Schiff, eds. Lippincott Williams and Wilkins, 2001 in press.
36. Levy, G.A., Lilly, L., Girgrah, N., and Catral, M.S. Immunologic Aspects of Liver Disease. In: Schiff's Diseases of the Liver, 9th ed, Vol 2. Lippincott Williams & Wilkins, Marlton, NJ, 2002, Chapter 35, pp.987.
37. Arya N., Girgrah N., Levy, G.A. Progress in understanding and Treatment of (HCV) Infection. In: McGraw-Hill 2003 Yearbook of Science and Technology, E.

Gary A. Levy, MD

Geller, ed., The McGraw-Hill Companies, Inc., pp. 168-171.